Profile data is unavailable for this security.
About the company
Jiangsu Hengrui Pharmaceuticals Co Ltd is a China-based company principally engaged in the manufacture and distribution of pharmaceutical tablets, injections and raw materials. The Company's main products portfolio consists of antineoplastic drugs, angiomyocardiac drugs, drugs for surgery, contrast agents, antibiotics, specialty infusions and others. The Company distributes its products within domestic market and to overseas markets.
- Revenue in CNY (TTM)26.00bn
- Net income in CNY5.45bn
- Incorporated1997
- Employees19.61k
- LocationJiangsu Hengrui Pharmaceuticals Co LtdNo.7 Kunlunshan RoadLianyungang Eco & Tech Development ZoneLIANYUNGANG 222000ChinaCHN
- Phone+86 51 881220983
- Fax+86 51 885453845
- Websitehttps://www.hengrui.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shanghai Fosun Pharmaceutical (Group) | 41.61bn | 2.11bn | 65.25bn | 40.37k | 34.60 | 1.54 | -- | 1.57 | 0.7883 | 0.7883 | 15.54 | 17.71 | 0.3682 | 2.86 | 5.10 | 1,030,748.00 | 2.44 | 4.31 | 4.18 | 7.01 | 47.10 | 50.71 | 6.63 | 10.65 | 0.7221 | -- | 0.3755 | 31.92 | -5.81 | 10.69 | -36.04 | -2.50 | 10.95 | -3.34 |
| Sichuan Biokin Pharmaceutical Co Ltd | 5.85bn | 3.80bn | 79.84bn | 2.09k | 21.01 | 18.82 | -- | 13.65 | 9.48 | 9.48 | 14.58 | 10.58 | 1.40 | 1.81 | 64.16 | 2,802,843.00 | 90.79 | -- | 138.20 | -- | 95.33 | -- | 64.99 | -- | 2.89 | -- | 0.2807 | -- | -20.11 | -- | -176.40 | -- | -- | -- |
| Beijing Wantai Biolog Pha Ent Co Ltd | 2.49bn | -294.04m | 90.79bn | 3.84k | -- | 7.31 | -- | 36.46 | -0.2393 | -0.2393 | 1.97 | 9.82 | 0.1596 | 0.7843 | 0.7758 | 647,931.10 | -1.89 | 24.08 | -2.26 | 31.80 | 69.01 | 85.18 | -11.84 | 34.95 | 4.18 | -- | 0.0238 | 9.88 | -50.73 | 41.18 | -73.65 | 33.61 | 36.35 | -- |
| Zhangzhou Pientzhng Phrmctcl Co Ltd | 10.91bn | 3.08bn | 149.08bn | 2.79k | 48.41 | 10.63 | -- | 13.67 | 5.10 | 5.10 | 18.08 | 23.24 | 0.6401 | 1.67 | 14.66 | 3,911,417.00 | 18.22 | 18.82 | 22.51 | 23.91 | 43.91 | 46.55 | 28.46 | 27.98 | 3.64 | -- | 0.0747 | 36.49 | 15.69 | 16.11 | 13.15 | 19.60 | 13.83 | 31.06 |
| Jiangsu Hengrui Pharmaceuticals Co Ltd | 26.00bn | 5.45bn | 321.88bn | 19.61k | 59.37 | 7.35 | -- | 12.38 | 0.8499 | 0.8499 | 4.06 | 6.86 | 0.57 | 1.57 | 4.60 | 1,325,555.00 | 11.94 | 13.68 | 12.99 | 15.20 | 84.88 | 85.87 | 20.94 | 20.01 | 8.34 | -- | 0.002 | 23.77 | 7.26 | 5.55 | 10.14 | 1.14 | 22.90 | 9.45 |
Data as of Nov 21 2024. Currency figures normalised to Jiangsu Hengrui Pharmaceuticals Co Ltd's reporting currency: Chinese Yuan Renminbi CNY
11.42%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| E Fund Management Co., Ltd.as of 30 Sep 2024 | 158.65m | 2.49% |
| China Asset Management Co., Ltd.as of 30 Jun 2024 | 132.37m | 2.08% |
| China Universal Asset Management Co., Ltd.as of 30 Jun 2024 | 87.67m | 1.38% |
| Zhong Ou Asset Management Co., Ltdas of 30 Sep 2023 | 79.46m | 1.25% |
| ICBC Credit Suisse Asset Management Co., Ltd.as of 30 Jun 2024 | 61.86m | 0.97% |
| China Investment Corp. (Investment Management)as of 30 Sep 2023 | 58.11m | 0.91% |
| Huatai-PineBridge Fund Management Co., Ltd.as of 30 Jun 2024 | 55.00m | 0.86% |
| Harvest Fund Management Co., Ltd.as of 30 Jun 2024 | 33.92m | 0.53% |
| Capital Research & Management Co. (World Investors)as of 07 Nov 2024 | 30.55m | 0.48% |
| GF Fund Management Co., Ltd.as of 30 Jun 2024 | 29.58m | 0.46% |
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
